« Back
Preclinical Evaluation of EZH2 Inhibition in Combination with Bcl-2 Inhibition in Diffuse Large B-cell Lymphoma
Poster Title: Preclinical Evaluation of EZH2 Inhibition in Combination with Bcl-2 Inhibition in Diffuse Large B-cell Lymphoma
Submitted on 08 Feb 2018
Author(s): Herman van Besien, Destini Gibbs, Ari Melnick, Ethel Cesarman, and Lisa G. Roth
Affiliations: USF Health Morsani College of Medicine, Weill Cornell Medical College
This poster was presented at USF Health Research Day 2018
Poster Views: 610
View poster »

Poster Information
Abstract: Objectives
1. Determine the single-drug efficacy of EZH2 inhibitors in Diffuse Large B-Cell Lymphoma.

2. Identify potential candidates for combination therapy with EZH2 inhibitors.

3. Determine synergy of combination therapy in vivo.

We evaluated the effect of EPZ-6438, ABT-199, and their combination in a panel of GCB-DLBCL cell lines (SUDHL-4, SUDHL-6, WSU-DLCL2, OCI-LY1, OCI-LY7, and Farage). SUDHL-4, SUDHL-6, WSU-DLCL2, and OCI-LY1 harbor an activating mutation in EZH2 and a translocation involving Bcl-2. OCI-LY7 and Farage are WT for EZH2 and do not harbor Bcl2 translocations. EZH2 inhibitors have a delayed effect on cell viability, with maximal effect observed at days 6-10. In our combination experiments, we treated cells with EPZ-6438 for six days prior to adding ABT-199. Viability was assessed 24, 48 and 72 hours after adding ABT-199 using an ATP-based luminescence assay. Results were normalized to the vehicle-treated control. We also performed synergy experiments using the same treatment schedule but with escalating doses of EPZ-6438 and ABT-199, and calculated combination indices (CI) using the Chou-Talalay method. A CI value <1 is considered synergistic.

SUDHL-6 and WSU-DLCL2 were both sensitive to EPZ-6438 and ABT-199 as single agents. SUDHL-6 and WSU-DLCL2 demonstrated increased sensitivity to the combination of EPZ-6438 and ABT-199, compared to cells treated with vehicle, (p=0.0001 for SUDHL-6; 0.0001 for WSU-DLCL2) EPZ-6438 alone, (p=0.004 for SUDHL-6; 0.0002 for WSU-DLCL2) and ABT-199 alone (p=0.0001 for SUDHL-6; 0.0012 for WSU-DLCL2). Isobolograms indicated synergy with this combination (CI at ED50=0.11980 for SUDHL-6, 0.26779 for WSU-DLCL2).

We have found that the combination of EPZ-6438 and ABT-199 is synergistic in some DLBCL cells harboring EZH2 mutation and Bcl2 translocations. We will further characterize the optimal timing of this combination and validate results in the in-vivo setting.
Summary: The EZH2 histone methyltransferase is a lineage factor for germinal center B cells, and EZH2 inhibitors are toxic to the germinal center B-cell subtype of diffuse large B cell lymphoma. We performed a drug screening that identified potential synergy between EZH2 and Bcl2 inhibition. We used the selective Bcl-2 inhibitor ABT-199 to perform in-vitro combination experiments with the EZH2 inhibitor EPZ-6438.References: Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677-692.
Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890-896.
McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108-112.
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon

Platinum™ SuperFi™ DNA Polymerase for the highest success in PCR
Rasa Sukackaitė, Martyna Simutytė, Skaistė Valinskytė, Laurynas Vanagas, Karolis Matjošaitis, Renata Rimšelienė, Remigijus Skirgaila.

DNA-free Platinum Taq DNA polymerase for reliable microbiome studies
Kęstutis Bargaila, Vytautas Budrys, Andrius Krasauskas, Dovilė Lisauskienė, Milda Romeikaitė, Sonata Jurėnaitė-Urbanavičienė,Ramunė Leipuvienė and Juozas Šiurkus

riboPOOL: Affordable Custom/Ribosomal RNA Depletion Against Any Species for RNA-Seq
Catherine Goh1, Andrew Walsh1, Michaela Beitzinger1, Jonas Bertram1, Kristina Döring3, Sascha Dietrich3, Iana Kim4, Stefan Kotschote2, Claus Kuhn4, Konrad Förstner3, Michael Bonin2, Stefan Hannus1, Michael Hannus1

The Good, the Bad and the Ugly: Selective single cell isolation
Sandra Lubos1,2, Nils Körber1, Heide Marie Resch1, Iris Augustin2, Stefan Niehren1